Crescent Biopharma, Inc. (CBIO)
Nasdaq: CBIO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2003
Who owns Crescent Biopharma, Inc.
As filed with the SECHolders of 5% or more
9
Peter Harwin holds 16.5% of Ordinary Shares, $0.001 par value, as its SCHEDULE 13D/A filed Jul 20, 2026 says.
Directors and officers
16
report now, of 35 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 9 named at left.
Holders of 5% or moreshare of the class, as filed
Peter Harwin
SCHEDULE 13D/A · filed Jul 20, 2026 · Ordinary Shares, $0.001 par value · 18.5% in Dec 8, 2025
Fmr LLC
SCHEDULE 13G/A · filed Feb 5, 2026 · COMMON STOCK · 10.2% in Jul 8, 2025
1Globe Capital LLC
SCHEDULE 13G/A · filed Oct 14, 2025 · Ordinary Shares, par value $0.001 per share · 6.45% in Aug 20, 2025
Bvf Partners L P/il
SCHEDULE 13G/A · filed Aug 14, 2025 · Ordinary Shares, $0.001 par value per share
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Ordinary Shares, $0.001 par value per share · 9.9% in Jun 23, 2025
ForGrowth III PA B.V.
SCHEDULE 13G · filed Dec 11, 2025 · Ordinary Shares, $0.001 par value per share
Balyasny Asset Management L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 5.48% in May 15, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock
Vestal Point Capital, LP
SCHEDULE 13G · filed Feb 17, 2026 · Ordinary Shares, par value $0.001 per share
Tang Capital Management, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Ordinary Shares, $0.001 par value per share · reported falling below 5%, from 5.04% in Oct 9, 2025
Logos Global Management LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Ordinary Shares · reported falling below 5%
Adage Capital Management, L.P.
SCHEDULE 13D/A · filed Jun 20, 2025 · Ordinary Shares, par value $0.001 per share · reported falling below 5%
Weinstein Benjamin
SCHEDULE 13G/A · filed Nov 4, 2024 · Common Stock, $0.001 par value · reported falling below 5%, from 5.3% in Aug 14, 2024
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
What CBIO reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Reverse Recapitalization of GlycoMimetics
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
Insider tradesForm 4
16sales
2purchases
16sales on a scheduled plan
7people selling
$1.5Msold, in dollars
$30.6Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 55 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Brumm Joshua T | Chief Executive Officer | 3 | $900,000 | 3 | 0 | $0 |
| Mcneill Jonathan | President and COO | 3 | $400,000 | 3 | 0 | $0 |
| Fairmount Healthcare Fund II L.P. | director | 0 | $0 | 0 | 1 | $12.4M |
| Harwin Peter Evan | director | 0 | $0 | 0 | 1 | $18.2M |
| Lynch Ryan | Treasurer, Senior Vice President of Finance and Chief Accounting Officer. | 2 | $0 | 2 | 0 | $0 |
| Scalzo Richard William | Chief Financial Officer | 2 | $0 | 2 | 0 | $0 |
| Im Ellie Eunkyung | Chief Medical Officer | 2 | $0 | 2 | 0 | $0 |
| Pinkas Jan | Chief Scientific Officer | 2 | $0 | 2 | 0 | $0 |
| Bispham Barbara Harlin | General Counsel and Corporate Secretary. | 2 | $0 | 2 | 0 | $0 |